Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

41 42 Next >

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M ↗

June 16, 2023

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that

Via Benzinga

Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review ↗

June 16, 2023

Stocks kept powering higher despite, but the Nasdaq is looking extended.

Via Investor's Business Daily

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million ↗

June 15, 2023

Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.

Via Investor's Business Daily

Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating ↗

June 14, 2023

B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a

Via Benzinga

Health Care Company Novartis Announces Merger With Chinook Therapeutics ↗

June 12, 2023

Via Benzinga

Is Novartis a Good Stock to Buy Right Now? ↗

June 07, 2023

The multinational pharma giant excels as an income play.

Via The Motley Fool

Looking At Novartis's Recent Unusual Options Activity ↗

June 01, 2023

Via Benzinga

Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis ↗

May 22, 2023

Via Benzinga

KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook ↗

June 12, 2023

Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock.

Via InvestorPlace

Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover ↗

June 12, 2023

Novartis will pay $3.5 billion to buy the kidney disease-focused biotech company.

Via Investor's Business Daily

XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust ↗

June 12, 2023

Find out more about two big winners Monday morning.

Via The Motley Fool

Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories ↗

June 12, 2023

Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger

Via Benzinga

Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today? ↗

June 12, 2023

Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS).

Via InvestorPlace

Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker ↗

May 04, 2023

Eylea sales fell and missed expectations in the U.S.

Via Investor's Business Daily

Is This Big Pharma Stock a Buy for Dividend Investors? ↗

April 27, 2023

The Swiss pharmaceutical giant possesses a tremendous product pipeline.

Via The Motley Fool

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 12, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

Via InvestorPlace

Why Are Chinook Therapeutics Shares Trading Higher Today ↗

June 12, 2023

Novartis AG (NYSE: NVS) has agreed to acquire Chinook Therapeutics Inc (NASDAQ: KDNY) for $40 per share in cash,

Via Benzinga

Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗

June 12, 2023

Via Benzinga

Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories ↗

June 08, 2023

Wall Street Journal

Via Benzinga

Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations ↗

June 08, 2023

Novartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its

Via Benzinga

Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis ↗

May 22, 2023

Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program...

Via Benzinga

Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis ↗

May 22, 2023

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...

Via Benzinga

Why Is AVROBIO (AVRO) Stock Up 83% Today? ↗

May 22, 2023

AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS).

Via InvestorPlace

Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗

May 09, 2023

Via Benzinga

What's Going On With Immix Biopharma Stock Today ↗

May 03, 2023

Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'

Via Benzinga

Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents ↗

May 03, 2023

Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several...

Via Benzinga

Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗

May 02, 2023

Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen

Via Benzinga

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels ↗

April 26, 2023

Novartis AG (NYSE: NVS) released detailed

Via Benzinga

After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines ↗

April 25, 2023

In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam.

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

Headline News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today